List of publications using NVP-TAE684 (Axon 1416) purchased from Axon Medchem 

(Total 9 publication citations listed; updated on JUNE 2016)
 
2016
Grygielewicz, P., Dymek, B., Bujak, A., Gunerka, P., Stanczak, A., Lamparska-Przybysz, M., ... & Zdzalik, D. (2016). Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. Gastric Cancer, 19(1), 53-62.
http://link.springer.com/article/10.1007/s10120-014-0444-1 
 
2015
Zhang, I., Zaorsky, N. G., Palmer, J. D., Mehra, R., & Lu, B. (2015). Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. The Lancet Oncology, 16(13), e510-e521.
http://www.sciencedirect.com/science/article/pii/S1470204515000133
 
Simionato, F., Frizziero, M., Carbone, C., Tortora, G., & Melisi, D. (2015). Current Strategies to Overcome Resistance to ALK-Inhibitor Agents. Current drug metabolism, 16(7), 585-596.
http://www.ingentaconnect.com/content/ben/cdm/2015/00000016/00000007/art00008 
 
2014
Martinengo, C., Poggio, T., Menotti, M., Scalzo, M. S., Mastini, C., Ambrogio, C., ... & Pastorino, F. (2014). ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. Cancer research, 74(21), 6094-6106.
http://www.ncbi.nlm.nih.gov/pubmed/25193384 
 
Tan, J., Li, Z., Lee, P. L., Guan, P., Aau, M., Lee, S. T., ... & Yu, Q. (2013). PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy. Cancer discovery.
Read more: http://cancerdiscovery.aacrjournals.org/content/early/2013/08/17/2159-8290.CD-12-0595.abstract
(*NVP-TAE684 and other 60 inhibitors are procured from Axon Medchem)


2013

Kancha, R. K., Bartosch, N., & Duyster, J. (2013). Analysis of Conformational Determinants Underlying HSP90-Kinase Interaction. PloS one, 8(7), e68394.
Read more: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0068394

2011
Yan, X., Kennedy, C. R., Tilkens, S. B., Wiedemeier, O., Guan, H., Park, J. I., & Chan, A. M. (2011). Cooperative cross-talk between neuroblastoma subtypes confers resistance to anaplastic lymphoma kinase inhibition. Genes & cancer, 2(5), 538-549.
Read more: http://gan.sagepub.com/content/2/5/538.short

Heuckmann, J. M., Hölzel, M., Sos, M. L., Heynck, S., Balke-Want, H., Koker, M., ... & Thomas, R. K. (2011). ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research, 17(23), 7394-7401.
Read more: http://clincancerres.aacrjournals.org/content/17/23/7394.short

Reiff, T., Huber, L., Kramer, M., Delattre, O., Janoueix-Lerosey, I., & Rohrer, H. (2011). Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development, 138(21), 4699-4708.
Read more: http://dev.biologists.org/content/138/21/4699.short

(This is an incomplete list, updated JUNE-2016) 

Please wait...